DD

Business profile & competitive position

DuPont de Nemours, Inc. operates in the Basic Materials sector under the Chemicals industry. After separating its Electronics Business and treating Electronics, Aramids, and the historical M&M businesses as discontinued operations, the company now reports through two segments: Healthcare & Water Technologies and Diversified Industrials. Its continuing operations supply differentiated technologies such as medical packaging and devices, water filtration and purification products, building-envelope and interior solutions, industrial adhesives, lubricants, engineered shapes, and printing plates.

The company’s intellectual property base is material: it owned roughly 6,100 patents and patent applications globally at year-end 2025, with about 4,700 associated with continuing operations, and more than 70% of that continuing-operations patent estate had a remaining term of more than five years. Its geographic footprint is also broad—subsidiaries in about 50 countries, manufacturing in about 20 countries, and roughly 15,000 employees worldwide, including about 1,700 tied to the soon-to-be-sold Aramids business.

Where the profit-profile picture weakens is in the current returns. With a net margin of 0.7% and return on equity of 0.3%, DuPont is not presently converting its technology and scale into strong bottom-line performance. Those figures do not, on their own, point to a deep competitive moat; instead, they suggest trailing earnings are being depressed by restructuring, separation costs, or legacy exposures. The investment case hinges on whether the narrower,Healthcare & Water and Diversified Industrials portfolio can eventually produce margins that look more like a differentiated chemicals company than the current 0.7% bottom line implies.

Financial posture

DuPont currently carries an $18.1 billion market capitalization and trades at a trailing P/E of 291.2. Against that valuation, the 0.7% net margin and 0.3% ROE stand out as extremely low; the stock is priced at a large multiple of recent earnings, which implies the market is either anticipating a meaningful earnings recovery or viewing trailing net income as temporarily depressed by discontinued operations and one-time items. Either way, the valuation is not being supported by the latest reported profitability.

The balance-sheet snapshot is somewhat incomplete in the data provided, since no specific debt figure is listed. What is visible is a beta of 1.09, meaning the stock has shown slightly more sensitivity to broad market movements than the average equity. In a cyclical chemicals business, that modestly elevated beta is consistent with exposure to industrial demand, raw-material costs, and capital-market sentiment.

Strategic priorities & outlook

The company’s most recent 10-K filing lays out a clear set of near-term priorities:

• Closing the sale of the Aramids business to Arclin, expected around the end of the first quarter of 2026, subject to closing conditions and regulatory approvals.
• Realizing the intended benefits of the Electronics Separation, including the targeted tax treatment and the contractual allocation of certain liabilities to Qnity.
• Executing the $2 billion share buyback authorization announced on November 6, 2025.
• Managing the arrangement to share future eligible PFAS costs among DuPont, Corteva, and Chemours, including litigation and remediation exposures.

Operationally, the fourth quarter of 2025 brought a realignment into the two current reportable segments, with prior financials recast as if the M&M, Aramids, and Electronics separations had occurred on January 1, 2023. The strategic message is simplification: fewer segments, cleaner comparable financials, and returned capital via the buyback. The offset is the PFAS-related overhang, which remains a contingent liability rather than a closed chapter.

Macro & geopolitical exposure

As a diversified chemicals company, DuPont is exposed to the standard macro and geopolitical forces that shape the industry. Feedstock and energy-price volatility feed directly into manufacturing costs, while trade policy and tariffs affect both raw-material inputs and finished-product sales across its roughly 20-country manufacturing footprint. Currency movement can swing translated international revenue. Regulatory scrutiny is elevated for chemical producers, particularly around environmental compliance, water discharge, emissions, and PFAS-related litigation and remediation. End-market demand is also cyclical: healthcare, water infrastructure, construction, and industrial activity all correlate with broader economic health. The 10-K’s emphasis on PFAS cost-sharing confirms that litigation and remediation risk is a real, ongoing exposure for this business model.

Recent developments

The August 2026 news flow highlighted DuPont’s narrower end markets. On August 20, 2026, Flow Cleanrooms & Supply expanded availability of DuPont Tyvek IsoClean and Tyvek 400 garments, according to Globe Newswire, underscoring healthcare and cleanroom demand. On August 17, 2026, Zacks reported that DuPont’s MemCor MBR system was chosen for a major plant upgrade in Australia, a tangible win for the water-technologies portfolio. Earlier, on August 13, 2026, PR Newswire noted that DuPont’s Direct Lithium Extraction team was named a 2026 Sustainability Squad by the Business Intelligence Group, pointing to exposure in resource-recovery and clean-technology markets. A broader sector read came from Zacks on August 18, 2026, which listed diversified chemical stocks as positioned to gain amid stable end-market demand.

Earnings behavior & post-earnings drift

DuPont’s earnings track record has been unusually strong relative to the market’s real expectation. Over the last eight reported quarters, the company beat estimates 8 out of 8 times, or 100%, with an average earnings surprise of 171.1%. The average 5-day price move after those reports was 2.83%, classified as an “up” post-earnings drift.

The last four reports illustrate both consistency and skew from a few extremely large beats:

• August 4, 2026: actual EPS of $1.88 versus an estimate of $1.76 (6.8% surprise); the stock rose 3.11% the next day and 1.09% over the following five days.
• May 5, 2026: actual EPS of $1.65 versus an estimate of $0.4881 (238% surprise); the stock rose 1.69% the next day and 2.64% over the next five days.
• February 10, 2026: actual EPS of $1.38 versus an estimate of $1.29 (7.0% surprise); the stock rose 4.25% the next day and 3.88% over the next five days.
• November 6, 2025: actual EPS of $3.27 versus an estimate of $0.4656 (602.3% surprise); the stock rose 1.66% the next day and 3.70% over the next five days.

The two triple-digit surprises—238% and 602.3%—heavily inflate the 171.1% average, so the more recent 6.8% to 7% beats are probably a better read of the current reporting environment. Even so, each of the last four reports produced positive next-day and 5-day moves, with the smallest one-day pop at 1.66% and the largest at 4.25%. The next scheduled report is November 5, 2026 before market open, with a consensus EPS estimate of $1.87. At a current price of $133.93, the stock sits below its 50-day EMA of $139.67 and carries an RSI of 38.5, which is approaching the lower end of the neutral range. Historical drift is descriptive, not predictive, but the pattern shows that DuPont has consistently cleared the market’s real expectation and generally experienced buying interest in the sessions that followed.

For a deeper dive into the full array of institutional ratings, consensus expectations, and valuation models behind this profile, take a look at the complete institutional verdict on the ticker’s dedicated research page.